Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Cell Max Life launches new genetic cancer risk test in US and India

MDBR Staff Writer Published 17 November 2016

Precision cancer testing company Cell Max Life has introduced its genetic cancer risk test in the US and India.

The CellMax-DNA genetic cancer risk test examines 98 genes across 24 hereditary cancers using the company's SMSEQ Platform

The test, which uses next generation sequencing to detect gene mutations, can identify increased risk of 24 cancers such as breast, lip, lung, colorectal, stomach, prostate, bladder, thyroid, ovary and others.

CellMax-DNA test is said to cover all BRCA1 and BRCA2, in addition to examining multiple other genes associated with breast cancer such as ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PPM1D, PTEN, RAD51C, RAD51D, STK11, TP53.

According to the company, genetic mutations associated with increased cancer risk are passed from parent to offspring, and individuals with certain inherited genetic mutations carry a higher lifetime risk for various cancers.

CellMax Life medical affairs vice president Mana Javey said: “Our goal is to make personalized, comprehensive cancer diagnostics affordable and accessible to every individual.

“By providing the industry’s broadest gene panel for hereditary cancer risk testing, we are enabling individuals and their physicians to do high-impact health planning.”

CellMax Life offers multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer.

The company also produces CellMax-CRC colorectal cancer screening product, which is a multi-biomarker blood test for early detection of colorectal cancer.